Equilis StrepE
live vaccine against Streptococcus equi
Table of contents
Overview
This is a summary of the European public assessment report (EPAR). Its purpose is to explain how the assessment done by the Committee for Medicinal Products for Veterinary Use (CVMP) on the basis of the documentation provided, led to the recommendations on the conditions of use.
This summary cannot replace a face-to-face discussion with your veterinarian. If you need more information about your animal’s medical condition or treatment, contact your veterinarian. If you want more information on the basis of the CVMP recommendations, read the scientific discussion (also part of the EPAR).
Authorisation details
Product details | |
---|---|
Name |
Equilis StrepE
|
Agency product number |
EMEA/V/C/000078
|
Active substance |
live deletion-mutant Streptococcus equi strain TW928
|
International non-proprietary name (INN) or common name |
live vaccine against Streptococcus equi
|
Species |
Horses
|
Anatomical therapeutic chemical veterinary (ATCvet) codes |
QI05AE
|
Publication details | |
---|---|
Marketing-authorisation holder |
Intervet International BV
|
Revision |
9
|
Date of issue of marketing authorisation valid throughout the European Union |
07/05/2004
|
Contact address |
Product information
10/04/2014 Equilis StrepE - EMEA/V/C/000078 - II/0012/G
Contents
- Annex I - Summary of product characteristics
- Annex IIA - Manufacturing-authorisation holder responsible for batch release
- Annex IIB - Conditions of the marketing authorisation
- Annex IIIA - Labelling
- Annex IIIB - Package leaflet
Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.
Pharmacotherapeutic group
Immunologicals for equidae
Therapeutic indication
For immunisation of horses against Streptococcus equi to reduce clinical signs and occurrence of lymph-node abscesses.
Onset of immunity: The onset of immunity is established as two weeks after basic vaccination.
Duration of immunity: The duration of immunity is up to three months.
The vaccine is intended for use in horses for which a risk of Streptococcus equi infection has been clearly identified, due to contact with horses from areas where this pathogen is known to be present, e.g. stables with horses that travel to shows or competitions in such areas, or stables that obtain or have livery horses from such areas.